New

Anti-influenza Drugs Market

2021

Anti-influenza Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Other Products); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others) and Geography

| Report Code: TIPRE00025692 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Anti-influenza Drugs Market 2028 By Product Type, Distribution Channel and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

The component of a drug that produces the desired effects is known as the active pharmaceutical ingredient (API). Combination therapies, for example, in long term treatments have various active substances that cure different symptoms or act in different ways. API is the potent component in drug formulation and often used with additives or excipients to improve therapeutic efficacy of a medicine. Many pharmaceutial companies develop their API by own or by outsourcing operations. Some common examples of API are, diclofenac, propanolol, methotraxate etc.

MARKET SCOPE

The "Global Active Pharmaceutical Ingredient (API) Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the active pharmaceutical ingredient (API) market with detailed market segmentation by type of synthesis and therapeutic application. The report provides key statistics on the market status of the leading active pharmaceutical ingredient (API) market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •   Based on type of synthesis the market is bifurcated as, biotech and synthetic.
  •   Based on therapeutic application the market is segmented as, cardiology, oncology, CNS and neurology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology and others.


MARKET DYNAMICS
Drivers:

  •   Significant growth in pharmaceutical & biotechnology companies.
  •   Growth in R&D activities across the companies to develop novel molecules and APIs.
  •   Increasing prevalnece of chronic diseases, idiosyncratic diseases and advancements in API production activities.

Restraints:

  •   Issues such as higher manufacturing costs and time consuming method of API development.
  •   Unfavorable DPCO guidelines are also expected to restrain market growth.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Active pharmaceutical ingredient (API) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Active pharmaceutical ingredient (API) market in these regions.

IMPACT OF COVID-19 ON ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. But some of the API molecules such as, remdesivir, favipiravir, and other such API have shown promising outcomes against covid-19 infection which has impacted positively on API market growth however, COVID-19 has disrupted all the business and economic activities across the globe which is expected to have some impact on active pharmaceutical ingredient (API) market. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Active pharmaceutical ingredient (API) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Active pharmaceutical ingredient (API) market are anticipated to lucrative growth opportunities in the future with the rising demand for Active pharmaceutical ingredient (API) in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Active pharmaceutical ingredient (API) market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Teva Pharmaceutical Industries Ltd.
  •   AbbVie Inc.
  •   Pfizer, Inc.
  •   Cipla Inc.
  •   Merck KGaA
  •   Bristol Myers Squibb
  •   GlaxoSmithKline plc
  •   Mylan N.V.
  •   Dr. Reddy's Laboratories Ltd
  •   Sun Pharmaceutical Industries Ltd

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-influenza Drugs - By Product type
1.3.2 Anti-influenza Drugs - By Distribution channel
1.3.3 Anti-influenza Drugs - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-INFLUENZA DRUGS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-INFLUENZA DRUGS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-INFLUENZA DRUGS - GLOBAL MARKET ANALYSIS
6.1. ANTI-INFLUENZA DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-INFLUENZA DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ANTI-INFLUENZA DRUGS - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. PERAMIVIR
7.3.1. Overview
7.3.2. peramivir Market Forecast and Analysis
7.4. ZANAMIVIR
7.4.1. Overview
7.4.2. zanamivir Market Forecast and Analysis
7.5. OSELTAMIVIR PHOSPHATE
7.5.1. Overview
7.5.2. oseltamivir phosphate Market Forecast and Analysis
7.6. BALOXAVIR MARBOXIL
7.6.1. Overview
7.6.2. baloxavir marboxil Market Forecast and Analysis
7.7. OTHER PRODUCTS
7.7.1. Overview
7.7.2. other products Market Forecast and Analysis
8. ANTI-INFLUENZA DRUGS - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. RETAIL PHARMACIES
8.3.1. Overview
8.3.2. retail pharmacies Market Forecast and Analysis
8.4. HOSPITAL PHARMACIES
8.4.1. Overview
8.4.2. hospital pharmacies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. others Market Forecast and Analysis
9. ANTI-INFLUENZA DRUGS REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti-influenza Drugs Overview
9.1.2 North America Anti-influenza Drugs Forecasts and Analysis
9.1.3 North America Anti-influenza Drugs Forecasts and Analysis - By Product type
9.1.4 North America Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.1.5 North America Anti-influenza Drugs Forecasts and Analysis - By Countries
9.1.5.1 United States Anti-influenza Drugs
9.1.5.1.1 United States Anti-influenza Drugs by Product type
9.1.5.1.2 United States Anti-influenza Drugs by Distribution channel
9.1.5.2 Canada Anti-influenza Drugs
9.1.5.2.1 Canada Anti-influenza Drugs by Product type
9.1.5.2.2 Canada Anti-influenza Drugs by Distribution channel
9.1.5.3 Mexico Anti-influenza Drugs
9.1.5.3.1 Mexico Anti-influenza Drugs by Product type
9.1.5.3.2 Mexico Anti-influenza Drugs by Distribution channel
9.2. EUROPE
9.2.1 Europe Anti-influenza Drugs Overview
9.2.2 Europe Anti-influenza Drugs Forecasts and Analysis
9.2.3 Europe Anti-influenza Drugs Forecasts and Analysis - By Product type
9.2.4 Europe Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.2.5 Europe Anti-influenza Drugs Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti-influenza Drugs
9.2.5.1.1 Germany Anti-influenza Drugs by Product type
9.2.5.1.2 Germany Anti-influenza Drugs by Distribution channel
9.2.5.2 France Anti-influenza Drugs
9.2.5.2.1 France Anti-influenza Drugs by Product type
9.2.5.2.2 France Anti-influenza Drugs by Distribution channel
9.2.5.3 Italy Anti-influenza Drugs
9.2.5.3.1 Italy Anti-influenza Drugs by Product type
9.2.5.3.2 Italy Anti-influenza Drugs by Distribution channel
9.2.5.4 Spain Anti-influenza Drugs
9.2.5.4.1 Spain Anti-influenza Drugs by Product type
9.2.5.4.2 Spain Anti-influenza Drugs by Distribution channel
9.2.5.5 United Kingdom Anti-influenza Drugs
9.2.5.5.1 United Kingdom Anti-influenza Drugs by Product type
9.2.5.5.2 United Kingdom Anti-influenza Drugs by Distribution channel
9.2.5.6 Rest of Europe Anti-influenza Drugs
9.2.5.6.1 Rest of Europe Anti-influenza Drugs by Product type
9.2.5.6.2 Rest of Europe Anti-influenza Drugs by Distribution channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti-influenza Drugs Overview
9.3.2 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis
9.3.3 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Product type
9.3.4 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.3.5 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Countries
9.3.5.1 Australia Anti-influenza Drugs
9.3.5.1.1 Australia Anti-influenza Drugs by Product type
9.3.5.1.2 Australia Anti-influenza Drugs by Distribution channel
9.3.5.2 China Anti-influenza Drugs
9.3.5.2.1 China Anti-influenza Drugs by Product type
9.3.5.2.2 China Anti-influenza Drugs by Distribution channel
9.3.5.3 India Anti-influenza Drugs
9.3.5.3.1 India Anti-influenza Drugs by Product type
9.3.5.3.2 India Anti-influenza Drugs by Distribution channel
9.3.5.4 Japan Anti-influenza Drugs
9.3.5.4.1 Japan Anti-influenza Drugs by Product type
9.3.5.4.2 Japan Anti-influenza Drugs by Distribution channel
9.3.5.5 South Korea Anti-influenza Drugs
9.3.5.5.1 South Korea Anti-influenza Drugs by Product type
9.3.5.5.2 South Korea Anti-influenza Drugs by Distribution channel
9.3.5.6 Rest of Asia-Pacific Anti-influenza Drugs
9.3.5.6.1 Rest of Asia-Pacific Anti-influenza Drugs by Product type
9.3.5.6.2 Rest of Asia-Pacific Anti-influenza Drugs by Distribution channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti-influenza Drugs Overview
9.4.2 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis
9.4.3 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Product type
9.4.4 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.4.5 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti-influenza Drugs
9.4.5.1.1 South Africa Anti-influenza Drugs by Product type
9.4.5.1.2 South Africa Anti-influenza Drugs by Distribution channel
9.4.5.2 Saudi Arabia Anti-influenza Drugs
9.4.5.2.1 Saudi Arabia Anti-influenza Drugs by Product type
9.4.5.2.2 Saudi Arabia Anti-influenza Drugs by Distribution channel
9.4.5.3 U.A.E Anti-influenza Drugs
9.4.5.3.1 U.A.E Anti-influenza Drugs by Product type
9.4.5.3.2 U.A.E Anti-influenza Drugs by Distribution channel
9.4.5.4 Rest of Middle East and Africa Anti-influenza Drugs
9.4.5.4.1 Rest of Middle East and Africa Anti-influenza Drugs by Product type
9.4.5.4.2 Rest of Middle East and Africa Anti-influenza Drugs by Distribution channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti-influenza Drugs Overview
9.5.2 South and Central America Anti-influenza Drugs Forecasts and Analysis
9.5.3 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Product type
9.5.4 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.5.5 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti-influenza Drugs
9.5.5.1.1 Brazil Anti-influenza Drugs by Product type
9.5.5.1.2 Brazil Anti-influenza Drugs by Distribution channel
9.5.5.2 Argentina Anti-influenza Drugs
9.5.5.2.1 Argentina Anti-influenza Drugs by Product type
9.5.5.2.2 Argentina Anti-influenza Drugs by Distribution channel
9.5.5.3 Rest of South and Central America Anti-influenza Drugs
9.5.5.3.1 Rest of South and Central America Anti-influenza Drugs by Product type
9.5.5.3.2 Rest of South and Central America Anti-influenza Drugs by Distribution channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-INFLUENZA DRUGS
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTI-INFLUENZA DRUGS, KEY COMPANY PROFILES
12.1. ASTRAZENECA PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BIOCRYST PHARMACEUTICALS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. DAIICHI SANKYO COMPANY, LIMITED.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. F. HOFFMANN-LA ROCHE LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MYLAN N.V.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SANOFI
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SEQIRUS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

- AstraZeneca plc
- BIOCRYST PHARMACEUTICALS, INC.
- DAIICHI SANKYO COMPANY, LIMITED.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Mylan N.V.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Seqirus
TIPRE00025692
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.